Cemex S.A.B. De C.V. Sponsored (NYSE:CX) shares traded 0.92% up during most recent session to reach at the closing price of $8.81. The stock exchanged hands 4.03 Million shares versus average trading capacity of 9.18 Million shares, yielding a market cap of $12.79 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $10 within the next 52-weeks. The mean target projections are based on 18 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Cemex S.A.B. De C.V. Sponsored (NYSE:CX) high price target of $11.54 and with a conservative view have low price target of $8.16.

Morgan Stanley “Upgrades” Cemex S.A.B. De C.V. Sponsored (NYSE:CX) in a research note issued to investors on 4/04/17 to Overweight with price target of $11.

Additionally on 3/31/17 Longbow Research “Upgrades” Cemex S.A.B. De C.V. Sponsored (NYSE:CX) to Buy setting price target at $12 and on 11/09/16 Bank of America “Downgrades” the stock to Neutral at $0. Furthermore on 9/06/16 Goldman Sachs “Initiates Coverage on” the stock to Buy at $10.4.

On the other hand the company has Relative Strength Index (RSI 14) of 52.07 along with Average True Range (ATR 14) of 0.23, Consequently Cemex S.A.B. De C.V. Sponsored (NYSE:CX)’s weekly and monthly volatility is 1.86%, 2.52% respectively. The company’s beta value is at 1.48.

In terms of Buy, Sell or Hold recommendations, Cemex S.A.B. De C.V. Sponsored (NYSE:CX) has analysts’ mean recommendation of 2.3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Cemex S.A.B. De C.V. Sponsored (NYSE:CX)’s minimum EPS for the current quarter is at $0.12 and can go high up to $0.2. The consensus mean EPS for the current quarter is at $0.16 derived from a total of 4 estimates from the analysts who have weighed in on projected earnings. However the company reported $0.12 earnings per share for the same quarter during last year.

Previously Cemex S.A.B. De C.V. Sponsored (NYSE:CX) reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.09. The company posted an earnings surprise of 180%.

While considering growth estimates of the company, it has next quarter growth estimates of -10% whereas during current quarter it has 33.3% estimations over growth, comparing to the estimations of 17% during current year and 14.5% for next year. Past 5 years growth of Cemex S.A.B. De C.V. Sponsored (NYSE:CX) observed at -53.14%, looking forward for the next 5 years it has a strong prediction of 10.6% over growth.

Cemex S.A.B. De C.V. Sponsored (NYSE:CX)’s revenue estimates for the current quarter are $3.71 Billion according to 3 number of analysts, for the current quarter the company has high revenue estimates of $3.75 Billion in contradiction of low revenue estimates of $3.64 Billion. For the current year the company’s revenue estimates are $13.98 Billion compared to low analyst estimates of $13.37 Billion and high estimates of $15.12 Billion according to 16 number of analysts.

Currently Cemex S.A.B. De C.V. Sponsored (NYSE:CX)’s shares owned by insiders are 60%, whereas shares owned by institutional owners are 38.6%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded -1.15%.

Cemex S.A.B. De C.V. Sponsored (NYSE:CX) 52-week high price stands at $9.25 and low price stands at $5.28, its price distance from 52-week high is -4.76% while its distance from 52-week low price is 66.89%. The stock hit its 52-week high on 04/05/17, and 52-week low on 06/27/16.

Cemex S.A.B. De C.V. Sponsored (NYSE:CX)’s trailing twelve month revenues are $13.61 Billion, whereas its price to sales ratio for the same period is 0.93. Its book value per share for the most recent quarter is $5.87 while its price to book ratio for the same period is 1.5, as for as the company’s cash per share for the most recent quarter is $0.52, however its price to cash per share ratio for the same period is 17.07. The stock has 5 year expected PEG ratio of 1.54 whereas its trailing twelve month P/E ratio is 16.35.